Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials - Merck.com
Merck discontinues two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, evaluating KEYTRUDA in different cancer treatments due to lack of efficacy and safety concerns. KEYNOTE-867, testing KEYTRUDA with SBRT for NSCLC, showed no improvement in EFS or OS and higher AEs. KEYNOTE-630, assessing KEYTRUDA for adjuvant treatment of high-risk cSCC, was stopped for futility as it did not meet RFS significance. Safety profiles were consistent with established data. Merck advises patients to consult their physicians for next steps.
Related Clinical Trials
Reference News
Merck discontinues two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, evaluating KEYTRUDA in different cancer treatments due to lack of efficacy and safety concerns. KEYNOTE-867, testing KEYTRUDA with SBRT for NSCLC, showed no improvement in EFS or OS and higher AEs. KEYNOTE-630, assessing KEYTRUDA for adjuvant treatment of high-risk cSCC, was stopped for futility as it did not meet RFS significance. Safety profiles were consistent with established data. Merck advises patients to consult their physicians for next steps.
Merck discontinued phase 3 trials KEYNOTE-867 and KEYNOTE-630 assessing pembrolizumab in NSCLC and CSCC due to lack of efficacy and unfavorable risk/benefit profiles. KEYNOTE-867 failed to improve EFS or OS, while KEYNOTE-630 did not meet RFS primary endpoint. Both trials were halted based on independent data monitoring committee recommendations.
Merck discontinued phase 3 trials KEYNOTE-867 and KEYNOTE-630 assessing pembrolizumab in NSCLC and CSCC due to lack of efficacy and unfavorable risk/benefit profiles. KEYNOTE-867 failed to improve EFS or OS, while KEYNOTE-630 did not meet RFS significance. Both trials were halted based on independent data monitoring committee recommendations.